Dong-A ST Co., Ltd. (KRX:170900)

Market Cap	344.58B -19.5%
Revenue (ttm)	860.94B +15.4%
Net Income	8.69B
EPS	888.73
Shares Out	9.64M
PE Ratio	40.23
Forward PE	12.17
Dividend	666.67 (1.81%)
Ex-Dividend Date	Mar 10, 2026

Volume	3,119
Open	35,150
Previous Close	35,750
Day's Range	35,150 - 36,100
52-Week Range	31,600 - 56,381
Beta	0.41
Analysts	Buy
Price Target	56,952.38 (+59.31%)
Earnings Date	Oct 29, 2026

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 1,649
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 170900

Financial Performance

In 2025, Dong-A ST's revenue was 808.78 billion, an increase of 15.89% compared to the previous year's 697.87 billion. Losses were -28.59 billion, 2237.8% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for 170900 stock is "Buy." The 12-month stock price target is ₩56,952, which is an increase of 59.31% from the latest price.

Price Target

₩56,952

(59.31% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 17, 2026

Data Sources Report a data error